In DDN’s Weekly Rundown, we covered the removal of mRNA-related language from grants, the latest updates on H5N1 research, positive results from a T cell immunotherapy, and more! Read about this week’s top drug discovery news here: https://bit.ly/4j0L3Kb
Drug Discovery News
图书期刊出版业
Wilmington ，Delaware 8,180 位关注者
Exploring drug discovery and development
关于我们
Drug Discovery News provides engaging stories about scientific breakthroughs that will help life science researchers develop diagnostic and therapeutic approaches for improving human health. Read the latest drug development news at drugdiscoverynews.com.
- 网站
-
https://drugdiscoverynews.com/
Drug Discovery News的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 11-50 人
- 总部
- Wilmington ，Delaware
- 类型
- 私人持股
- 创立
- 2005
- 领域
- drug discovery and development、life science research、pharmaceuticals、biotechnology、publishing、clinical trials、biopharmaceuticals、diagnostics、biomarkers、cancer research、journalism、translational research和preclinical research
地点
-
主要
获取路线
1000 N West Street, Suite 1200
US，Delaware，Wilmington ，19801
Drug Discovery News员工
-
Cliff Dominy PhD
Medical Writer * Science Communicator * Translator of peer-reviewed literature * Journalist, lecturer & tutor for all things molecular.
-
Rajesh Kumar
News Editor/ Reporter at DDNews
-
Hannah Thomasy
Fellowship in Global Journalism at Dalla Lana School of Public Health, University of Toronto
-
Nidhi kumar
Celebrity show host on Indias public broadcaster at DD NEWS and DD NATIONAL, Ministry of Science, and Technology, Media lead and ambassador at Mitron…
动态
-
Serotonin decreases in the cerebellum during anxiety, opposite to other brain regions. Could the "little brain" become a novel target for future anti-anxiety treatments? Read more: https://bit.ly/3RgOTTg
-
-
Scientists are leveraging phages to deliver CRISPR-based gene-editing tools to modulate harmful microbes without eradicating them. This approach offers precision treatments for conditions like acne and gut infections while preserving microbiome balance. Read more: https://bit.ly/4iClCOX
-
-
The FDA recently approved the first non-opioid pain medication developed by Vertex Pharmaceuticals. “It's really exciting for the field. We haven't had a win in a very long time,” Ted Price told Allison Whitten. Read more about the new drug in this story: https://bit.ly/42ckdce
-
-
Judy Sebolt-Leopold at University of Michigan and her team at MEKanistic Therapeutics have pioneered the first dual-hit kinase inhibitor to treat cancers. Read more about their exciting discovery and future plans: https://bit.ly/4iwdzDn
-
-
An ancient Cas12a enzyme reconstructed from a three-billion-year-old bacterium widens gene editing capabilities to even more regions of the genome. Read more: https://bit.ly/3XVq2Ir
-
-
Most cancer cells are aneuploid — they have the wrong number of chromosomes. Researchers like Rameen Beroukhim, Alison Taylor, Stefano Santaguida, PhD, and Uri Ben-David are working on ways to harness this flaw to kill cancer cells. Read more: https://bit.ly/4iGvHdl
-
-
Catch up on the most significant drug discovery and development news from this week with the Weekly Rundown from Drug Discovery News, brought to you by editors Stephanie DeMarco, PhD, Allison Whitten, and Dika Ojiakor, Ph.D.. Get the updates, here: https://bit.ly/3DJRuSH
-
-
Researchers at Alltrna are developing tRNA-based therapeutics for various rare genetic diseases caused by similar mutations. Michelle Werner, CEO and Director of Alltrna, told Dika Ojiakor about how these medicines work and the company's efforts to bring them to the clinic. Read more: https://bit.ly/4iGxqzg
-
-
“These are the most efficacious medications that I have seen in my clinical practice in almost five decades,” Michael Camilleri at Mayo Clinic told Allison Whitten about GLP-1 drugs. But what are their side effects in patients? Read this story to learn more: https://bit.ly/4iI2A9w
-